|
|
 |
International Clinical Trials in Gastroenterology
Algeria
Argentina
Australia
Austria
Bangladesh
Belgium
Brazil
Bulgaria
Canada
- Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
Calgary, AR; Research Site
- Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
Edmonton, AB; Research Site
- Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
Kelowna, BC; Research Site
- Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
Montreal, QC; Research Site
- Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
Toronto, ON; Research Site
- Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
Winnipeg, MB; Research Site
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Brampton, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Edmonton, AB; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Greenfield Park, QC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Kelowna, BC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Levis, QC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
London, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Mississauga, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Moncton, NB; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Montreal, QC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Oshawa, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Ottawa, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Quebec City, QC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Surrey, BC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Sydney, NS; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Thunder Bay, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Toronto, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Vancouver, BC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Victoria, BC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Weston, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Winnipeg, MB; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Barrie, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Brampton, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Calgary, AB; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Edmonton, AB; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Greenfield Park, QC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Halifax, NS; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Kelowna, BC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Kingston, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Kitchener, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Laval, QC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Levis, QC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Mississauga, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Moncton, NB; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Montreal, QC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
New Westminster, BC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Newmarket, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Oshawa, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Ottawa, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Quebec City, QC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Regina, SK; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Saskatoon, SK; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Sault Ste Marie, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Scarborough, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
St John'S; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
St-Jerome, QC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Sudbury, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Surrey, BC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Sydney, NS; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Toronto, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Toronto, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Vancouver, BC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Victoria, BC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Weston, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Windsor, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Winnipeg, MB; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
Calgary, AB; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
Halifax, NS; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
Montreal, QC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
Ottawa, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
Toronto, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
Vancouver, BC; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Brampton, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Hamilton, ON; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Toronto, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Calgary, AB; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Edmonton, AB; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Halifax, NS; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Hamilton, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Kelowna, BC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Levis, QC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Mississauga, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Montreal, QC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
North Vancouver, BC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Oshawa, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Ottawa, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Quebec City, QC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
St. Catharines, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Surrey, BC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Toronto, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Vancouver, BC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Victoria, BC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Weston, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Winnipeg, MB; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Calgary, AB; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Kelowna, BC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Montreal, QC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Ottawa, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Saskatoon, SK; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Winnipeg, MB; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
Hamilton, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
Ottawa, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
Toronto, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Edmonton, AB; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Halifax, NS; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Laval, QC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Levis, QC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
London, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Montreal, QC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Oshawa, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Ottawa, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Quebec City, QC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Regina, SK; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
St John'S; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
St. Catharines, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Thunder Bay, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Toronto, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Weston, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Calgary, AB; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Edmonton, AB; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Halifax, NS; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Hamilton, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Kelowna, BC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Laval, QC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Levis, QC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
London, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Mississauga, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Montreal, QC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Oshawa, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Ottawa, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Quebec City, QC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
St John'S; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Surrey, BC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Toronto, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Victoria, BC; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Weston, ON; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Winnipeg, MB; Research Site:
- Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
Abbotsford, British Columbia; UCB Clinical Trial Call Center
- Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
Calgary, Alberta; UCB Clinical Trial Call Center
- Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
Edmonton, Alberta; UCB Clinical Trial Call Center
- Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
London, Ontario; UCB Clinical Trial Call Center
- Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
Saskatoon, Saskatchewan; UCB Clinical Trial Call Center
- Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
Toronto, Ontario; UCB Clinical Trial Call Center
- Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
Toronto, Ontario; UCB Clinical Trial Call Center
- Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
Vancouver, British Columbia; UCB Clinical Trial Call Center
- Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
Vancouver, British Columbia; UCB Clinical Trial Call Center
- Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
Winnipeg, Manitoba; UCB Clinical Trial Call Center
- Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Abbottsford, British Columbia; UCB Clinical Trial Call Center
- Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Calgary; UCB Clinical Trial Call Center
- Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Edmonton, Alberta; UCB Clinical Trial Call Center
- Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
London, Ontario; UCB Clinical Trial Call Center
- Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Saskatoon, Saskatchewan; UCB Clinical Trial Call Center
- Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Toronto, Ontario; UCB Clinical Trial Call Center
- Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Toronto, Ontario; UCB Clinical Trial Call Center
- Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Vancouver, British Columbia; UCB Clinical Trial Call Center
- Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Winnipeg, Manitoba; UCB Clinical Trial Call Center
- Crohn's Disease (Pediatric): Would you be interested in participating in a pediatric clinical research trial with treatment for Pediatric Crohn’s Disease?
Ottawa, Ontario; Research Site
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Edmonton, AB; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Toronto, ON; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Edmonton, AB; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Montreal, QC; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Ottawa, ON; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Quebec City, QC; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Toronto, ON; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Vancouver, BC; Research Site:
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Vancouver, British Columbia; Liver and Intestinal Research Centre
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Montreal, Quebec; Hôpital Maisonneuve - Rosemont
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Montreal, Quebec; Montreal General Hospital
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Saskatoon, SK; Medical Digestive
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Kingston, Ontario; Hotel Dieu Hospital - Kingston
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Quebec; CHAUQ - Hopital du St-Sacrement
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
London, Ontario; London Health Science Centre
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Hamilton, Ontario; McMaster University Health Sciences Center
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Victoria, British Columbia; PerCuro Clinical Research Ltd.
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Calgary, Alberta; University of Calgary
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Saskatoon, SK; Edwin Larkai Medical Professional Corporation
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Toronto, Ontario; Toronto Digestive Disease Associates, Inc.
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Toronto, Ontario; Sunnybrook Health Sciences Centre
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Winnipeg, MB; Health Sciences Centre
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Montreal, Quebec; Jewish General Hospital
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Montreal, Quebec; CHUM Hopital Saint-Luc
- Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Ottawa, Ontario; Hassard, Philip MD
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Calgary, Alberta; University of Calgary
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Quebec; CHAUQ - Hopital du St-Sacrement
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Kingston, Ontario; Hotel Dieu Hospital - Kingston
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Saskatoon, SK; Medical Digestive
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Saskatoon, SK; Edwin Larkai Medical Professional Corporation
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Victoria, British Columbia; PerCuro Clinical Research Ltd.
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Toronto, Ontario; Sunnybrook Health Sciences Centre
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Toronto, Ontario; Toronto Digestive Disease Associates, Inc.
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Vancouver, British Columbia; Liver and Intestinal Research Centre
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
London, Ontario; London Health Science Centre
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Hamilton, Ontario; McMaster University Health Sciences Center
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Winnipeg, MB; Health Sciences Centre
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Montreal, Quebec; Hôpital Maisonneuve - Rosemont
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Montreal, Quebec; Montreal General Hospital
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Montreal, Quebec; Jewish General Hospital
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Montreal, Quebec; CHUM Hopital Saint-Luc
- Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
Ottawa, Ontario; Hassard, Philip MD
China
| |
